The emergence of CAR T-cell therapies has revolutionized treatment for certain advanced hematological malignancies but remains limited in scope. With extensive research and clinical trials underway, there are significant opportunities to expand the applications and accessibility of CAR T-cell therapies by improving safety, efficacy, and cost. This white paper explores the history and current landscape of CAR T-cell therapy, highlighting advancements in CAR design, manufacturing, and combination therapies. Strategies to manage off-tumor toxicities, enhance efficacy, and reduce costs are examined, aiming to broaden access and address unmet medical needs.

Join for free to read